» Articles » PMID: 27098097

From Molecular Interaction to Acute Promyelocytic Leukemia: Calculating Leukemogenesis and Remission from Endogenous Molecular-cellular Network

Overview
Journal Sci Rep
Specialty Science
Date 2016 Apr 22
PMID 27098097
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Acute promyelocytic leukemia (APL) remains the best example of a malignancy that can be cured clinically by differentiation therapy. We demonstrate that APL may emerge from a dynamical endogenous molecular-cellular network obtained from normal, non-cancerous molecular interactions such as signal transduction and translational regulation under physiological conditions. This unifying framework, which reproduces APL, normal progenitor, and differentiated granulocytic phenotypes as different robust states from the network dynamics, has the advantage to study transition between these states, i.e. critical drivers for leukemogenesis and targets for differentiation. The simulation results quantitatively reproduce microarray profiles of NB4 and HL60 cell lines in response to treatment and normal neutrophil differentiation, and lead to new findings such as biomarkers for APL and additional molecular targets for arsenic trioxide therapy. The modeling shows APL and normal states mutually suppress each other, both in "wiring" and in dynamical cooperation. Leukemogenesis and recovery under treatment may be a consequence of spontaneous or induced transitions between robust states, through "passes" or "dragging" by drug effects. Our approach rationalizes leukemic complexity and constructs a platform towards extending differentiation therapy by performing "dry" molecular biology experiments.

Citing Articles

Predictive modelling of acute Promyelocytic leukaemia resistance to retinoic acid therapy.

Sanchez-Villanueva J, NGuyen L, Poplineau M, Duprez E, Remy E, Thieffry D Brief Bioinform. 2025; 26(1.

PMID: 39807666 PMC: 11729720. DOI: 10.1093/bib/bbaf002.


6-Gingerol modulates miRNAs and PODXL gene expression via methyltransferase enzymes in NB4 cells: an in silico and in vitro study.

Afgar A, Ramezani Zadeh Kermani M, Pabarja A, Afgar A, Kavyani B, Arezoomand H Sci Rep. 2024; 14(1):18356.

PMID: 39112503 PMC: 11306743. DOI: 10.1038/s41598-024-68069-4.


Potential therapeutic targets of gastric cancer explored under endogenous network modeling of clinical data.

Zhang X, Chen Y, Yao M, Xiong R, Liu B, Zhu X Sci Rep. 2024; 14(1):13127.

PMID: 38849404 PMC: 11161650. DOI: 10.1038/s41598-024-63812-3.


Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia.

Alvarez-Zuniga C, Garza-Veloz I, Martinez-Rendon J, Ureno-Segura M, Delgado-Enciso I, Martinez-Fierro M Cancers (Basel). 2023; 15(16).

PMID: 37627214 PMC: 10453581. DOI: 10.3390/cancers15164186.


Roadmap on plasticity and epigenetics in cancer.

Foo J, Basanta D, Rockne R, Strelez C, Shah C, Ghaffarian K Phys Biol. 2022; 19(3).

PMID: 35078159 PMC: 9190291. DOI: 10.1088/1478-3975/ac4ee2.


References
1.
Ottersbach K, Smith A, Wood A, Gottgens B . Ontogeny of haematopoiesis: recent advances and open questions. Br J Haematol. 2009; 148(3):343-55. DOI: 10.1111/j.1365-2141.2009.07953.x. View

2.
Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E . Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001; 193(12):1361-71. PMC: 2193303. DOI: 10.1084/jem.193.12.1361. View

3.
Peck D, Crawford E, Ross K, Stegmaier K, Golub T, Lamb J . A method for high-throughput gene expression signature analysis. Genome Biol. 2006; 7(7):R61. PMC: 1779561. DOI: 10.1186/gb-2006-7-7-r61. View

4.
Theilgaard-Monch K, Jacobsen L, Borup R, Rasmussen T, Bjerregaard M, Nielsen F . The transcriptional program of terminal granulocytic differentiation. Blood. 2004; 105(4):1785-96. DOI: 10.1182/blood-2004-08-3346. View

5.
Walker L, Browning D, Miyamoto A, Weinmaster G, Gasson J . Notch signaling enhances survival and alters differentiation of 32D myeloblasts. J Immunol. 2000; 165(8):4428-36. DOI: 10.4049/jimmunol.165.8.4428. View